Mucopolysaccharidosis type III or Sanfilippo syndrome is an autosomal recessive lysosomal disease caused by pathogenic variants in SGSH, NAGLU, HGSNAT or GNS. Deficiency of these enzymes blocks the degradation of heparan sulfate and produces intralysosomal accumulation with predominant involvement of the central nervous system.
Mucopolysaccharidosis type 3
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is an autosomal recessive lysosomal storage disorder caused by biallelic variants in one of four genes: SGSH, NAGLU, HGSNAT, or GNS. These alterations prevent the proper degradation of heparan sulfate, which progressively accumulates, especially in the central nervous system.
MPS III comprises four subtypes defined by the affected gene and enzyme: SGSH in type A, NAGLU in type B, HGSNAT in type C, and GNS in type D. Lysosomal accumulation of heparan sulfate leads to predominantly neurological involvement, with progressive cognitive, behavioral, and motor deterioration.
Symptoms
The onset usually occurs in childhood, with speech delay, hyperactivity, sleep disorders, and behavioral problems. With progression, developmental regression appears, loss of cognitive and motor skills, gait disturbances, seizures, hearing loss, and recurrent respiratory infections. Classic forms can evolve into severe intellectual disability and progressive dependence.
Disease management
There is currently no approved curative treatment that effectively modifies the main neurological impairment. Management is multidisciplinary and supportive, including control of sleep disorders, behavior, epilepsy, feeding, infections, and motor limitations. Gene therapies, intrathecally administered enzymes, and substrate reduction therapies are being investigated.
Genes analyzed
Bibliography
Wagner VF, Northrup H. Mucopolysaccharidosis Type III. GeneReviews®.
Romagnoli AS, Campos LN, Fernandez-Guzman D, et al. Evaluating Patients With Mucopolysaccharidosis Type III: A Scoping Review on Diagnostic and Follow-Up Approaches. J Appl Res Intellect Disabil. 2025.
